Zydus Lifesciences Gains US FDA Approval for Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg Dosages

Zydus Lifesciences Gains US FDA Approval for Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg Dosages

Zydus Lifesciences Limited has obtained final approval […] The post Zydus Lifesciences Gains US FDA Approval for Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg Dosages first appeared on GeneOnline News. The post Zydus Lifesciences Gains US FDA Approval for Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg Dosages appeared first on GeneOnline News.

Zydus receives final approval from US FDA for Verapamil Hydrochloride

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (US FDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg). Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like st…